||Clinical trial updates: Low-molecular-weight heparin
- The slide shows anti-Xa activity in the 24 hours following administration of the low-dose enoxaparin regimen described in the previous slide.1
- As shown, regardless of concomitant administration of GP IIb/IIIa inhibitor (eptifibatide), a high and constant degree of anticoagulation was maintained throughout the procedure.
1 Choussat R, Montalescot G, Collet JP, Vicaut E, Ankri A, Gallois V, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol. 2002;40:1943-1950.